



(11)

EP 3 635 129 B8

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C12Q 1/6886 ^(2018.01)

(86) International application number:
PCT/EP2018/064479

(48) Corrigendum issued on:
15.09.2021 Bulletin 2021/37

(87) International publication number:
WO 2018/224406 (13.12.2018 Gazette 2018/50)

(45) Date of publication and mention
of the grant of the patent:
28.07.2021 Bulletin 2021/30

(21) Application number: **18727021.0**

(22) Date of filing: **01.06.2018**

(54) **METHODS FOR CHARACTERIZING LOSS OF ANTIGEN PRESENTATION**

VERFAHREN ZUR CHARAKTERISIERUNG DES VERLUSTES VON ANTIGENPRÄSENTATION
PROCÉDÉS DE CARACTÉRISATION DE PERTE DE PRÉSENTATION DE L'ANTIGÈNE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

- **SUCHAN, Martin**
55129 Mainz (DE)
- **SCHRÖRS, Barbara**
55124 Mainz (DE)
- **LÖWER, Martin**
55131 Mainz (DE)
- **OEHM, Petra**
55131 Mainz (DE)

(30) Priority: **09.06.2017 PCT/EP2017/064112**

(43) Date of publication of application:
15.04.2020 Bulletin 2020/16

(74) Representative: **Schnappauf, Georg**
ZSP Patentanwälte PartG mbB
Hansastraße 32
80686 München (DE)

(60) Divisional application:
21186973.0

(73) Proprietors:
• **BioNTech SE**
55131 Mainz (DE)
• **TRON - Translationale Onkologie an der**
Universitätsmedizin der Johannes Gutenberg-
Universität Mainz gemeinnützige GmbH
55131 Mainz (DE)

(56) References cited:
• **D'URSO C M ET AL: "LACK OF HLA CLASS I**
ANTIGEN EXPRESSION BY CULTURED
MELANOMA CELLS FO-1 DUE TO A DEFECT IN
B2M GENE EXPRESSION", JOURNAL OF
CLINICAL INVESTIGATION, AMERICAN
SOCIETY FOR CLINICAL INVESTIGATION, US,
vol. 87, 1 January 1991 (1991-01-01), pages
284-292, XP002051964, ISSN: 0021-9738, DOI:
10.1172/JCI114984

(72) Inventors:
• **SAHIN, Ugur**
55131 Mainz (DE)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 635 129 B8

- ANNETTE PASCHEN ET AL: "Complete loss of HLA class I antigen expression on melanoma cells: A result of successive mutational events : HLA Class I Antigen Loss", INTERNATIONAL JOURNAL OF CANCER, vol. 103, no. 6, 12 December 2002 (2002-12-12), pages 759-767, XP055399467, US ISSN: 0020-7136, DOI: 10.1002/ijc.10906
- A. PASCHEN ET AL: "The Coincidence of Chromosome 15 Aberrations and 2-Microglobulin Gene Mutations Is Causative for the Total Loss of Human Leukocyte Antigen Class I Expression in Melanoma", CLINICAL CANCER RESEARCH, vol. 12, no. 11, 1 June 2006 (2006-06-01), pages 3297-3305, XP055399450, US ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-05-2174
- MONICA BERNAL ET AL: "Implication of the Î2-microglobulin gene in the generation of tumor escape phenotypes", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 61, no. 9, 26 July 2012 (2012-07-26), pages 1359-1371, XP035103281, ISSN: 1432-0851, DOI: 10.1007/S00262-012-1321-6